BRIEF-Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses In The Fully Enrolled Bcg-Naïve Cohort Of The Ongoing Phase 2 Advanced-2 Trial Of Tara-002 In Nmibc

Protara Therapeutics, Inc.

Protara Therapeutics, Inc.

TARA

0.00

Protara Therapeutics Inc TARA.O:

  • PROTARA THERAPEUTICS ANNOUNCES POSITIVE UPDATED 12-MONTH DATA DEMONSTRATING DURABLE RESPONSES IN THE FULLY ENROLLED BCG-NAÏVE COHORT OF THE ONGOING PHASE 2 ADVANCED-2 TRIAL OF TARA-002 IN NMIBC

  • PROTARA THERAPEUTICS: TARA-002 DEMONSTRATES 72% COMPLETE RESPONSE RATE AT ANY TIME, 67% COMPLETE RESPONSE RATE AT 6-MONTH LANDMARK

  • PROTARA THERAPEUTICS INC: TARA-002 DEMONSTRATES 55% COMPLETE RESPONSE RATE AT 12-MONTH LANDMARK

  • PROTARA THERAPEUTICS INC: TARA-002 SHOWED FAVORABLE SAFETY AND TOLERABILITY PROFILE

  • PROTARA THERAPEUTICS INC: ON TRACK TO INITIATE ADVANCED-3 REGISTRATIONAL TRIAL IN BCG-NAÏVE PATIENTS IN 2H 2026

Source text: ID:nGNX7hsP38

Further company coverage: TARA.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.